Method of treating the symptoms of Alzheimer's disease

• US 5,284,664 A
• Filed: 02/05/1992
• Issued: 02/08/1994
• Est. Priority Date: 08/04/1988
• Status: Expired due to Fees

• Current Assignee: Kremers Urban LLC
• Original Assignee: Kremers Urban LLC
• Inventors: Wagle, Sudhakar S., Gawish, Ali A. S., Hermann, William J., Steinbach, Thomas, Lawyer, Carl H.
• Primary Examiner(s): Robinson, Douglas W.
• Assistant Examiner(s): Witz, Jean C.
• Application Number:
  US07/835,029
• Time in Patent Office: 734 Days
• Field of Search: 424/553
• US Class Current: 424/553
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/407 Liver; Hepatocytes
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 14/4711 Alzheimer's disease; Amyloid plaque core protein

Abstract

A therapeutic method for treating Alzheimer'"'"'s or related disease. The method comprises administering a therapeutically-effective amount of a mammalian liver extract, the extract being characterized by being heat stable, insoluble in acetone and soluble in water, peptide or peptide fragment selected from the groups consisting of Sequence Identification Numbers 1-9.

Claims

1. A method of treating the symptoms of Alzheimer'"'"'s disease comprising administering a therapeutically effective amount of a mammalian liver extract which is referred herein as KU 10,001, wherein the extract is heat stable, insoluble in acetone and soluble in water.

2. The method of claim 1 wherein the liver extract is a porcine liver extract.

3. The method of claim 1 wherein the liver extract is in a pharmaceutically-acceptable carrier at a concentration of about 2.5% by weight solids.

4. The method of claim 2 wherein the liver extract is in a pharmaceutically-acceptable carrier at a concentration of about 2.5% by weight solids.

5. The method of claim 4 wherein the liver extract is in water.